Amryt Pharma advancing on multiple fronts

0
12
  • Amryt Pharma raises sales forecast again as acquisition makes strong start
  • Amryt reports record 2Q results and raises full-year guidance as momentum continues to build
Amryt Pharma PLC -

Quick facts: Amryt Pharma PLC

Follow

View company profile

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

The company has a strong and growing portfolio of commercial and development assets.

13 Sep 2021

Amryt Pharma has raised its full-year 2021 revenue guidance due to a strong performance from recent acquisition of Chiasma and its own commercial products.

Revenues are now expected in a range of US220mln – $225mln compared to previous guidance of US$210mln- $215mln.

Joe Wiley, Amryt Pharma’s chief executive, said: “Given the strong performance of our business year to date and our recent acquisition of Chiasma, we are very pleased to once again increase our full-year 2021 revenue guidance to $220-$225 million which represents growth of 20%-23% on 2020.

“This latest upward revision of guidance demonstrates our confidence in the outlook for our underlying business and our visibility is further enhanced given that we have now begun the process of integrating Chiasma into Amryt and have begun to grow our combined business.”

Read more

06 Aug 2021

(, , ) has raised its full-year guidance after the biopharmaceutical company delivered a record set of results in its second quarter.

In its results for the quarter ended June 30, the company reported an operating profit before finance expense of US$4.1mln, swinging from a US$12mln loss a year ago, while revenues surged 35.9% to US$62.8mln.

Read more

05 Aug 2021

(, , ) has completed its acquisition of US group () with Raj Kannan and Roni Mamluk joining the board as non-executive directors.

Joe Wiley, Amryt’s chief executive, said: “This transaction further solidifies our position as a global leader in treating rare and orphan conditions.

Read more

06 Aug 2021

(, , ) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company’s second-quarter results, which show a 35.9% rise in revenue year-on-year.

Wiley noting that it’s the sixth consecutive quarter the company has reported positive EBITDA (core earnings) generation.

Given the strong performance year to date, Amryt has also raised its full-year 2021 revenue guidance to $210-$215 million.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt reports record 2Q results and raises full-year guidance as momentum…

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company’s second-quarter results, which show a 35.9% rise in revenue year-on-year.

Wiley noting that it’s the sixth consecutive quarter the company has reported positive EBITDA…

on 6/8/21

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here